`Aflibercept (WHO 2006)
`Ex 1008 (173 patent) SEQ 2
`
`
`
`SDTGRPFVEMYSEIPEIIHMTEGR 24
`
`SDTGRPFVEMYSEIPEIIHtITEGR 24
`
`MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTEGR 50
`
`U59254338 SEQ 2 (27-457)
`
`Aflibercept (WHO 2006)
`Ex 1008 (173 patent) SEQ 2
`
`ELVTPCRVTSPN ITVT LKKFPLDTLIPDGKRI IWDSRKGFIISNATYKEI 74
`ELVIPCRVTSPNITVTLKKFPLDTIIPDGKRI IW0SRKGFIISNATYKEI 74
`E LVIPCRVTSPN ITVTLKKFPLDT1IPDGKRI IW0SRKGFIISNATYKEI 100
`
`U59254338 SEQ 2 (27-457)
`Aflibercept (WHO 2006)
`Ex 1008 (173 patent) SEQ 2
`
`o LLTCEATVNGHLYKTNYLTHRQTNTI IDVVLSPSHG IELSVGEKLVLNC 124
`GLLTCEATVNGHLYKTNYLTHRQTNTI IDVVLSPSHGIELSVGEKLVLNC 124
`
`C LLTCEATVNG}-ILYKTNYLTHRQTNTI IDVVLSPSHCIELSVGEKLVLNC 150
`
`059254338 SEQ 2 (27-457)
`Aflibercept (WHO 2005)
`Ex 1008 (173 patent) SEQ 2
`
`TARTELNVCIDFNWEYPSSKHQHKKLVNRDLKTQSCSEMKKFLSTLTIDG 174
`TARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSCSEMKKF LSTLTIDS 174
`TARTELNVGI DFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDG 200
`
`0S9254338 SEQ 2 (27-457)
`Aflibercept (WHO 2006)
`Ex 1008 (173 patent) SEQ 2
`
`VTRSDQGLYTCAASSGLMTKKNSTFVRVHEKOKTHTCPPCPAPELLCCPS 224
`VTRSDQGLYTCAASSCLMTKKNSTFVRVHEKOKTHTCPPCPAPEL LOOPS 224
`VTRSDQGLYTCAASSCLMTKKNSTFVRVHEKOKTHTCPPCPAPEL LOOPS 250
`
`LJ59254338 SEQ 2 (27-457)
`Aflibercept (WHO 2006)
`
`VFLFPPKPKDTLMISRTPEVTCVVVOVSHEDPEVKFNWYVDGVEVHNAKT 274
`VF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH WAKT 274
`
`Ex 1008 (173 patent) SEQ 2
`
`VF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDCVEVHNAKT 300
`
`JS9254338 SEQ 2 (27-457)
`Aflibercept (WHO 2006)
`Ex 1008 (173 patent) SEQ 2
`
`KPREEQYNSTYRVVSVLTVLHQOWLNOKEYKCKVSNKALPAPI EKTISKA 324
`
`KPREEQYNSTVRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKA 324
`KPREEQYNSTYRVVSVLTVLHQDWLNOKEYKCKVSNKALPAPI EKTISKA 350
`
`059254338 SEQ 2 (27-457)
`Aflibercept (WHO 2006)
`Ex 1008 (173 patent) SEQ 2
`
`KGQP REPQVYT L PPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQPEN 374
`KGQP REPQVYT LPPSRDELTKN QVSLTC LVKGFYPSDI AVEWESNGQPEN 374
`KGQPREPQVYTLPPSRDEITKNQVSLTCLVKGFYPSDIAVEWESNCQPEN 400
`
`0S9254338 SEQ 2 (27-457)
`Aflibercept (WHO 2006)
`Ex 1008 (173 patent) SEQ 2
`
`NYKTTPPV LDSDGSFF LYS K LTVDKSRWQQGNVESCSVMHEALHNHYTQK 424
`NYKTTPPVLDSDCSFF LYSKLTVDKSRWQQGNVPSCSVMHEALI-INHYTQK 424
`
`NYKTTPPVLDSDGSFF LYSK LTVOKSRWQQGNVPSCSVMHEALHNHYTQK 450
`
`U59254338 SEQ 2 (27-457)
`Aflibercept (WHO 2006)
`Ex 1008 (173 patent) SEQ 2
`
`SLSLSPG- 431
`SLSISPG- 431
`SLSLSPGK 458
`
`Mylan Exhibit 1117
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`
`
`e
`
`0
`
`Mylan Exhibit 1117
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`Mylan Exhibit 1117
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`